Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data.
Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breas...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2023-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0287382 |
| _version_ | 1797799237833981952 |
|---|---|
| author | Kwang-Hee Shin Young-Mi Ah Sang Hun Cha Hye Duck Choi |
| author_facet | Kwang-Hee Shin Young-Mi Ah Sang Hun Cha Hye Duck Choi |
| author_sort | Kwang-Hee Shin |
| collection | DOAJ |
| description | Despite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription. |
| first_indexed | 2024-03-13T04:15:51Z |
| format | Article |
| id | doaj.art-b4abe50e986d40d09714de8695b127c8 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-03-13T04:15:51Z |
| publishDate | 2023-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-b4abe50e986d40d09714de8695b127c82023-06-21T05:30:58ZengPublic Library of Science (PLoS)PLoS ONE1932-62032023-01-01186e028738210.1371/journal.pone.0287382Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data.Kwang-Hee ShinYoung-Mi AhSang Hun ChaHye Duck ChoiDespite an increase in the use of targeted anticancer drugs and immunotherapy, cytotoxic anticancer drugs such as docetaxel continue to play a clinically important role. The aim of this study was to evaluate drug-drug interactions between docetaxel and coadministered medicines in patients with breast cancer a claims database. The Health Insurance Review and Assessment Service (HIRA) database (2017 to 2019) was used in this study. We evaluated the risk of neutropenia (defined using receipt of granulocyte colony-stimulating factor (G-CSF) prescriptions) under docetaxel administration or the coadministration of docetaxel and an interacting anticancer drug (predefined based on approval information obtained from the Korean Ministry of Food and Drug Safety and the Lexicomp electronic database). The propensity score matching method was applied to balance covariates in the case (patients with G-CSF prescriptions) and control (patients without G-CSF prescriptions) groups. We identified 947 female patients with breast cancer prescribed with docetaxel and excluded 321 patients based on inclusion criteria. Of the remaining 626 patients, 280 were assigned to the case group and 346 to the control group. Predefined drugs were coadministered to 71 (11.3%) patients during the 7-day period before and after the administration of docetaxel. Adjusted odds ratios (ORs) calculated using the logistic regression model applied to the propensity score matching showed no significant difference between the administration of docetaxel alone and docetaxel coadministration (adjusted OR, 2.010; 95% confidence interval, 0.906, 4.459). In conclusion, we suggest that coadministration of docetaxel and a predefined interacting drug are not associated with G-CSF prescription.https://doi.org/10.1371/journal.pone.0287382 |
| spellingShingle | Kwang-Hee Shin Young-Mi Ah Sang Hun Cha Hye Duck Choi Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. PLoS ONE |
| title | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. |
| title_full | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. |
| title_fullStr | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. |
| title_full_unstemmed | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. |
| title_short | Drug-Drug interactions of docetaxel in patients with breast cancer based on insurance claims data. |
| title_sort | drug drug interactions of docetaxel in patients with breast cancer based on insurance claims data |
| url | https://doi.org/10.1371/journal.pone.0287382 |
| work_keys_str_mv | AT kwangheeshin drugdruginteractionsofdocetaxelinpatientswithbreastcancerbasedoninsuranceclaimsdata AT youngmiah drugdruginteractionsofdocetaxelinpatientswithbreastcancerbasedoninsuranceclaimsdata AT sanghuncha drugdruginteractionsofdocetaxelinpatientswithbreastcancerbasedoninsuranceclaimsdata AT hyeduckchoi drugdruginteractionsofdocetaxelinpatientswithbreastcancerbasedoninsuranceclaimsdata |